Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer

Expert Opinion on Medical Diagnostics

Volumn 5, Issue 1, 2011, Pages 37-47

  Halin, Sofia ^a   Hammarsten, Peter ^a   Adamo, Hani ^a   Wikstrm, Pernilla ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cancer field effect; Diagnostic marker; Prognostic marker; Prostate biopsy; Prostate cancer; Tumor indicating normal tissue; Tumor stroma

Indexed keywords

ANDROGEN RECEPTOR; APC PROTEIN; BETA CATENIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE P1; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MITOCHONDRIAL DNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTATE STEM CELL ANTIGEN; PROTEIN PS2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER TISSUE; CELL STRUCTURE; CYTOLOGY; DISEASE SEVERITY; DNA CONTENT; DNA DAMAGE; DNA MICROARRAY; EPIGENETICS; GENE EXPRESSION; HUMAN; INFLAMMATORY CELL; INFRARED SPECTROSCOPY; LYMPH NODE METASTASIS; MAST CELL; METASTASIS; MICROSCOPY; MICROVASCULATURE; NEEDLE BIOPSY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROGNOSIS; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; REVIEW; STROMA; TELOMERE; TUMOR GROWTH;

EID: 78650566188     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2011.540009     Document Type: Review

References (97)

1. Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006;13(3):158-68 (Pubitemid 44469736)
2. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713-19 (Pubitemid 38725420)
3. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-21 (Pubitemid 351671887)
4. Andreoiu M, Cheng L. Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications. Hum Pathol 2010;41(6):781-93
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8
6. Toi A, Neill MG, Lockwood GA, et al. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007;177(2):516-20 (Pubitemid 46054011)
7. Raz O, Haider M, Trachtenberg J, et al. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010;7(10):543-51
8. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009;69(13):1470-9. Reviews the evidence for field cancerization in the prostate.
9. Partin AW. Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer? Curr Urol Rep 2000;1(4):245-51
10. Lawrentschuk N, Toi A, Lockwood GA, et al. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol 2009;182(6):2659-63
11. Hammarsten P, Karalija A, Josefsson A, et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 2010;16(4):1245-55. Describes that phosphorylated EGFR in normal glands is a prognostic TINT marker.
12. Wikstrom P, Marusic J, Stattin P, et al. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009;69(8):799-809. The first time the TINT concept, as a way to prognosticate cancer, was introduced.
13. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9(4):239-52. Reviews the role of the microenvironment in regulating growth of primary tumors and metastases.
14. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006;5(15):1597-601 (Pubitemid 44285243)
15. Psaila B, Kaplan RN, Port ER, et al. Priming the 'soil' for breast cancer metastasis: The pre-metastatic niche. Breast Dis 2006;26:65-74. Reviews the pre-metastatic niche concept.
16. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133(6):994-1005. Demonstrates how systemic signals from tumor convince other tissues and organs to help the tumor.
17. Chung LW, Baseman A, Assikis V, et al. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 2005;173(1):10-20. Reviews the important role of the prostate tumor microenvironment. (Pubitemid 39627663)
18. Cunha GR, Hayward SW, Wang YZ, et al. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107(1):1-10. Reviews the important role of the prostate tumor microenvironment.
19. Troester MA, Lee MH, Carter M, et al. Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 2009;15(22):7020-8. Demonstrated that the host response to the tumor is diagnostic and a potential target for therapy.
20. Auguste P, Fallavollita L, Wang N, et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007;170(5):1781-92 (Pubitemid 47339320)
21. Yu JL, Rak JW. Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003;5(2):83-8. Argues that the tumor-harboring organ has to adapt to the needs of the tumor.
22. McAllister SS, Weinberg RA. Tumor-host interactions: A far-reaching relationship. J Clin Oncol 2010;28(26):4022-8. Reviews how tumors affect and interact with adjacent and more remote tissues and organs.
23. Halin S, Rudolfsson SH, Doll JA, et al. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia 2010;12(4):336-45
24. Halin S, Rudolfsson SH, Van Rooijen N, et al. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009;11(2):177-86. Demonstrates that macrophages are recruited to the TINT to promote tumor growth.
25. Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010;177(2):1031-41. Defines accumulation of mast cells as a prognostic TINT marker.
26. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650-9. Postulates that tumor-host interactions are very similar to those in wounds.
27. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264(1):169-84 (Pubitemid 32989090)
28. Halin S, Hammarsten P, Wikstrom P, et al. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 2007;67(4):370-7. Demonstrates that the normal prostate tissue is adapted to the needs of the tumor and that castration is a TINT-targeted therapy. (Pubitemid 46341077)
29. Hammarsten P, Halin S, Wikstom P, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006;12(24):7431-6 (Pubitemid 46095418)
30. Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89(6):538-42 (Pubitemid 34948295)
31. Andren O, Fall K, Franzen L, et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175(4):1337-40 (Pubitemid 43312982)
32. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9(13):4792-801. Describes how stroma changes can be used to prognosticate prostate cancer. (Pubitemid 37323282)
33. Yanagisawa N, Li R, Rowley D, et al. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 2008;39(2):282-91. Describes how stroma changes can be used to prognosticate prostate cancer. (Pubitemid 47589095)
34. Bergh A. Characterization and functional role of the stroma compartment in prostate tumors. Future Oncol 2009;5(8):1231-5
35. Bacac M, Provero P, Mayran N, et al. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One 2006;1:e32
36. Richardson AM, Woodson K, Wang Y, et al. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol 2007;16(4):189-97 (Pubitemid 350196975)
37. Dakhova O, Ozen M, Creighton CJ, et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009;15(12):3979-89
38. Lissbrant IF, Lissbrant E, Damber JE, et al. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35(6):437-52 (Pubitemid 34066732)
39. Lissbrant IF, Stattin P, Wikstrom P, et al. Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival. Int J Oncol 2000;17(3):445-51
40. Karja V, Aaltomaa S, Lipponen P, et al. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005;25(6C):4435-8 (Pubitemid 41729492)
41. Fleischmann A, Schlomm T, Kollermann J, et al. Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009;69(9):976-81
42. Tammi RH, Kultti A, Kosma VM, et al. Hyaluronan in human tumors: Pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008;18(4):288-95
43. Olapade-Olaopa EO, MacKay EH, Taub NA, et al. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999;5(3):569-76
44. Hagglof C, Hammarsten P, Josefsson A, et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One 2010;5(5):e10747. Describes PDGFR expression as a prognostic TINT marker.
45. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10(19):6572-8. Describes pAKT as a prognostic TINT marker. (Pubitemid 39346553)
46. Merseburger AS, Hennenlotter J, Simon P, et al. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 2006;16(1):79-83
47. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7(2):1-12
48. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: Molecular evidence and clinical importance. Breast Cancer Res Treat 2009;118(2):229-39
49. DeMarzo AM, Nelson WG, Isaacs WB, et al. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361):955-64 (Pubitemid 36332115)
50. Josson S, Matsuoka Y, Chung LW, et al. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 2010;21(1):26-32. Reviews the importance of tumor-host interactions in prostate cancer.
51. Niu YN, Xia SJ. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009;11(1):28-35
52. Ge L, Meng W, Zhou H, et al. Could stroma contribute to field cancerization? Med Hypotheses 2010;75(1):26-31
53. Odefrey F, Stone J, Gurrin LC, et al. Common genetic variants associated with breast cancer and mammographic density measures that predict disease. Cancer Res 2010;70(4):1449-58
54. Graham K, de las Morenas A, Tripathi A, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 2010;102(8):1284-93
55. Moussa AS, Jones JS, Yu C, et al. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling. BJU Int 2010;106(9):1309-14
56. Johansson A, Jones J, Pietras K, et al. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 2007;67(15):1664-76 (Pubitemid 350036952)
57. Hirakawa S. From tumor lymphangiogenesis to lymphvascular niche. Cancer Sci 2009;100(6):983-9
58. Fujita K, Nakayama M, Nakai Y, et al. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Sci 2009;100(6):1047-50. First demonstration of prognostically useful TINT changes in lymph nodes in prostate cancer patients.
59. Cheng LL, Burns MA, Taylor JL, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65(8):3030-4. Demonstrates that the metabolite pattern is different in normal and cancer-adjacent prostate tissue and that the magnitude of this is of prognostic significance. (Pubitemid 40524579)
60. Heaphy CM, Fleet TM, Treat EG, et al. Organ-wide telomeric status in diseased and disease-free prostatic tissues. Prostate 2010;70(13):1471-9. Demonstrates that telomere length is reduced in the entire prostate harboring tumors and that the magnitude is related to distance from the tumor.
61. Mairinger T, Mikuz G, Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate 1999;41(1):12-9 (Pubitemid 29390411)
62. Veltri RW, Khan MA, Miller MC, et al. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-73
63. Isharwal S, Makarov DV, Carter HB, et al. DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme. BJU Int 2010;105(3):329-33. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate.
64. Montironi R, Diamanti L, Pomante R, et al. Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. J Pathol 1997;182(4):442-9 (Pubitemid 27317210)
65. Chandran UR, Dhir R, Ma C, et al. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5(45):1-11. Demonstrates that the gene-expression pattern is different in normal and cancer-adjacent prostate tissue. (Pubitemid 41461084)
66. Haaland CM, Heaphy CM, Butler KS, et al. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 2009;35(3):537-46
67. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22(14):2790-9 (Pubitemid 41079896)
68. Rizzi F, Belloni L, Crafa P, et al. A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One 2008;3(10):e3617
69. Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007;20(11):1121-7 (Pubitemid 47609070)
70. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21(2):67-75 (Pubitemid 351172158)
71. Zhao Z, Liu J, Li S, et al. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2009;69(12):1292-302. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate.
72. Ananthanarayanan V, Deaton RJ, Yang XJ, et al. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006;6(73):1-9 (Pubitemid 46277068)
73. Ananthanarayanan V, Deaton RJ, Yang XJ, et al. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer. Prostate 2005;63(4):341-6 (Pubitemid 40664346)
74. Santinelli A, Mazzucchelli R, Barbisan F, et al. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 2007;128(4):657-66 (Pubitemid 47584446)
75. Dhir R, Vietmeier B, Arlotti J, et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004;171(4):1419-23. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate. (Pubitemid 38365385)
76. Uetsuki H, Tsunemori H, Taoka R, et al. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005;174(2):514-18 (Pubitemid 40981588)
77. Hansel DE, DeMarzo AM, Platz EA, et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007;177(5):1736-40
78. Bonkhoff H, Stein U, Welter C, et al. Differential expression of the pS2 protein in the human prostate and prostate cancer: Association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26(8):824-8
79. Waalkes S, Simon P, Hennenlotter J, et al. Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. Oncol Rep 2010;23(5):1257-60
80. Slater M, Danieletto S, Barden JA. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol 2005;36(3):159-65. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate.
81. Huang D, Casale GP, Tian J, et al. Quantitative fluorescence imaging analysis for cancer biomarker discovery: Application to beta-catenin in archived prostate specimens. Cancer Epidemiol Biomarkers Prev 2007;16(7):1371-81. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate. (Pubitemid 47076866)
82. Henshall SM, Quinn DI, Lee CS, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001;61(2):423-7
83. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61(24):8617-23 (Pubitemid 34013865)
84. Hanson JA, Gillespie JW, Grover A, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006;98(4):255-61 (Pubitemid 43264709)
85. Henrique R, Jeronimo C, Teixeira MR, et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: Clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4(1):1-8 (Pubitemid 43259884)
86. Mehrotra J, Varde S, Wang H, et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008;68(2):152-60 (Pubitemid 351186227)
87. Aitchison A, Warren A, Neal D, et al. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007;67(6):638-44 (Pubitemid 46685284)
88. Krop I, Player A, Tablante A, et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004;2(9):489-94 (Pubitemid 39281730)
89. Malins DC, Gilman NK, Green VM, et al. A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 2005;102(52):19093-6
90. Malins DC, Gilman NK, Green VM, et al. Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci USA 2004;101(31):11428-31. Identifies a TINT change related to tumor aggressiveness.
91. Malins DC, Johnson PM, Barker EA, et al. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003;100(9):5401-6
92. Parr RL, Dakubo GD, Crandall KA, et al. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006;8(3):312-19
93. Robinson K, Creed J, Reguly B, et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 2010;13(2):126-31. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer in next set of biopsies.
94. Treat EG, Heaphy CM, Massie LW, et al. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology 2010;75(3):724-9. Demonstrates that shortened telomere length in TINT in prostate biopsies predicts outcome after surgery.
95. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75(10):2545-51
96. Montironi R, Diamanti L, Thompson D, et al. Analysis of the capillary architecture in the precursors of prostate cancer: Recent findings and new concepts. Eur Urol 1996;30(2):191-200 (Pubitemid 26285534)
97. Nonomura N, Takayama H, Kawashima A, et al. Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Sci 2010;101(6):1570-3. Demonstrates how TINT changes in tumor-free needle biopsies can be used to predict the presence of cancer elsewhere in the prostate.